Trial · NCT07159204
Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
NCT07159204, Phase 2, Recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer. Trials, record NCT07159204. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07159204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
- NCT number
- NCT07159204
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- Paclitaxel polymer micelle immunocombination
- First posted
- 2025-09-08
- Last updated
- 2026-10-15
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | From baseline until the earliest of documented disease progression, initiation of new anticancer therapy, or the primary outcome data cutoff, assessed up to 24 months. | Proportion of participants with a best overall response of complete response or partial response according to RECIST version 1.1, as assessed by investigators. Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance. |
| Secondary | Disease control rate | From baseline until the earliest of documented disease progression, initiation of new anticancer therapy, or the tumor response data cutoff, assessed up to 24 months. | Proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST version 1.1, as assessed by investigators. Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance. |
| Secondary | Progression-Free Survival (PFS) | From the first dose of study treatment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurred first, assessed up to 36 months. | Progression-free survival was defined as the time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurred first. |
| Secondary | Overall Survival (OS) | From the first dose of study treatment to death from any cause, assessed up to 36 months. | Overall survival was defined as the time from the first dose of study treatment to death from any cause. |
| Secondary | Safety and Tolerability | From signing informed consent through 28 days after the last dose of study treatment. | The incidence, type, and severity of adverse events, treatment-related adverse events, serious adverse events, and clinically significant abnormalities in laboratory test results and vital signs. Adverse events were graded according to NCI CTCAE version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28314319 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07159204
GET https://conductscience.org/api/trials/v1/NCT07159204/registered